Pricing, Reimbursement, Market Access - Pharmaceutical and Biotech industries
Nov 2018

Managed entry agreements lessons from EU5

Gain an insight into different approaches to managed entry agreements at national, regional, and local level by watching this webinar. Understand the practical implications for manufacturers, payers, and healthcare systems, and identify the considerations for the design of effective managed entry agreements

Learn more >>


Nov 2018

Meet with us at ISPOR Europe

Utilized by Market Access and HEOR professionals from affiliate to global level, the cutting edge PRMA digital applications unlock and optimize value from early product development through to successful HTA submissions. ISPOR Europe provides the perfect opportunity to experience the intuitive functionality of the secure and scalable applications.

Meet with us at ISPOR Europe >>


Oct 2018

Translate advances in oncology and gene therapy into successful market access strategy

Join our international senior team at ESMO 2018 to discuss your specific business challenges, examine global CAR-T insight from complex pricing experts and test-drive the latest, transformative digital applications.

Meet with us at ESMO >>


Oct 2018

CAR-T therapy: the future begins to take shape

What can HEOR and market access teams learn from CAR-Ts’ early pricing and reimbursement experience and health-system implementation plans? The current status and key issues for pricing and reimbursement of CAR-T therapy in the US, UK, France, and Germany are examined in this presentation. You will gain insight into the practical implications for health technology assessment, patient access, and the development of funding and delivery models within public healthcare systems for these breakthrough therapies.

Learn more >>


Oct 2018

Leading pharma launches new immunotherapy using insight from the PRMA Tracker®

To support the successful launch of a new immunotherapy for a fast-evolving indication, this noted pharmaceutical company required an in-depth understanding of the latest payer thinking across rapidly advancing global markets. Find out how they approached the challenge.

Read now >>


Sep 2018

Maximize the pricing and market access potential of your early pipeline

A top-10 pharmaceutical company sought to make informed decisions for an early pipeline product, with little data available. Find out how they established a consistent approach to comparative assessment of market access risks and opportunities to guide their early decision-making.

Read now >>


Sep 2018

Pricing and reimbursement insights for Gene Therapies

A recent meeting of complex pricing experts focused on the challenges and solutions for pricing and reimbursement in the area of innovative cell and gene therapy products. The bespoke group shared knowledge from a range of countries and different roles within healthcare systems, to bring a practical and pragmatic approach to issues related to pricing. We are pleased to share our highlights from this thought-leading meeting.

Read more >>


Sep 2018

Yescarta and Kymriah cell therapy: key areas to watch

With NICE’s rejection of Gilead’s Yescarta for treating DLBCL and NHS England’s announcement that a deal has been agreed with Novartis to fund Kymriah for childhood ALL, what are the implications for CAR-T manufacturers and assessment agencies?

Read more >>


Aug 2018

Achieving a variable price by indication: free eBook download

For manufacturers seeking to optimize the value of assets in development across multiple indications, there are alternative options to achieve a variable price by indication, other than the classic method of indication-specific rebates. Our free eBook helps you understand the variance in schemes and provides insight for selecting the most appropriate scheme.

Read now >>


Aug 2018

Over 40 readiness assessments successfully delivered by the PRMA Healthcheck® late module

PRMA Consulting is celebrating the successful support of over 40 readiness assessments using its digital application, the PRMA Healthcheck® late module. Created to drive payer submission readiness for Phase 2 and 3 products, the application is the result of 5 years’ collaboration with leading pharmaceutical companies to meet their market access challenges.

Read now >>


Payer perspectives on cell & gene therapy. Catch up with Professor Stephen Palmer’s thought-leading broadcast >> http://cgt.bz/21hsp

Aug 2018

Indication-based pricing: your free eBook download

Challenges for the commercialization of products that offer different value in different indications may be overcome with indication-based pricing strategies. This free eBook offers you insights into the key concepts and suggests ways to develop a value proposition.

Read now >>


Aug 2018

A smarter way to inform product strategy and planning dialogue

With the new version release of the PRMA Healthcheck® late module, you can inform high level conversations regarding product strategy and planning with an easily digestible synopsis of key vulnerabilities and proposed evidence generation projects. This is just one new way that our intuitive application helps you drive payer submission readiness for your Phase 2 and 3 products.

Read now >>


Jul 2018

Achieve up to 80% auto-population of your first draft HTA submission

A top-5 global pharma company investigated digital solutions from various companies to improve the quality and development timelines of simultaneous HTA submissions. The global team and affiliate countries selected the PRMA Navigator® application to auto-populate a partial submission for each country within 2 weeks.

Read now >>


Jul 2018

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma

Treatment decisions for advanced melanoma are increasingly complex as the landscape quickly evolves. This European expert panel study sought to understand which patient characteristics and disease-related factors inform clinicians' choices of first-line treatment for BRAF-mutated melanoma.

Read now >>


Jun 2018

Demonstrating product value through the revised ESMO value framework

This case study outlines the approach taken when a client sought to understand how changes to the ESMO-MCBS would affect the perceived value of their products and how these perceptions aligned with HTA outcomes.

Read now >>


May 2018

Experience our new digital applications

We warmly invite you to our drinks reception and demonstration of new digital applications at the ISPOR Global Conference in Baltimore, from 6pm on Monday 21 May and Tuesday 22 May on booth 807. This is the ideal opportunity to experience our latest solutions and discuss your specific market access challenges with members of our senior leadership team.

Meet with us at ISPOR Baltimore >>


May 2018

What role does the patient perspective play in determining access to innovative therapies?

Join us at ASCO 2018 to discover more about the differences between the EU and US perspectives on HRQL.

Meet with us at ASCO >>


May 2018

Indication-specific pricing: the obvious solution?

This presentation examines the opportunities and challenges for manufacturers and payers in implementing indication-based pricing strategies. You will gain an understanding of the complexities that multiple indication and combination products present for pricing and reimbursement and obtain actionable insights for developing a value proposition for indication-specific pricing.

Learn more >>


Apr 2018

Leveraging the value frameworks scoring of a new treatment and comparators

See the approach taken when a client sought to understand how various value frameworks would score their new treatment, in comparison to competitor products, and how this could be leveraged in the value proposition.

Read now >>


Apr 2018

Tailored solutions for early planning in market access

Visit booth 29 at DIA Europe and discover how we can help you develop an integrated early evidence strategy that anticipates and navigates complex market access requirements from pre-clinical development and beyond.

Meet with us at DIA Europe


Mar 2018

Value and Access: striking a balance
Join us in an expert discussion at DIA Europe

Ensuring optimal access at appropriate value is a balancing act. Our senior director, Jan McKendrick, is pleased to be participating in a thought leading discussion at DIA Europe which will address key questions on the topic taking into account multiple perspective. As part of the session, Jan will present international evidence of the impact of reimbursement and licensing discrepancies on patient access before a discussion on harmonisation and the path forward.

Visit booth 29 to discuss this with Jan in more detail.

Meet with us at DIA Europe


Mar 2018

3 reasons why an expert advisory group can help with your complex pricing challenges

Manufacturers seeking to execute complex pricing schemes rapidly and effectively need to approach payers with well-developed solutions, adapted to a range of country requirements and aligned with the changing landscape. Find out how an expert advisory group can help you with your complex pricing issues

Read now >>


Mar 2018

Payer perspectives on cell and gene therapies: 9 key challenges

Assessing payer perspectives on the rapid developments in regenerative medicines and cell therapy, we highlight the key challenges and opportunities for the clinical pipeline.

Read now >>


Feb 2018

CAR-Ts therapy and indication-specific pricing in Europe: new insights

A recent meeting of complex pricing experts from across the EU5 countries focused on the variability among countries of payers’ and policy-makers’ attitudes to innovative pricing, and the practical challenges for implementation of complex pricing schemes capable of satisfying a range of country requirements and accommodating the rapidly evolving landscape. We are pleased to share our highlights from this thought-leading meeting.


Feb 2018

Running the half-marathon for Addison's Disease Self-Help Group

A team of colleagues from PRMA Consulting are challenging themselves by running the Fleet half-marathon in March; for one of the group this will be a training run for the Rotterdam marathon a few weeks later!

Through our running, we would like to raise awareness and much needed funds for the Addison's Disease Self-Help Group. We recently became aware of the impact of this disease on a young child and his family; thankfully he survived and is learning to live with his condition.

Thank you for taking the time to visit our JustGiving page.


Dec 2017

Launch of the expert advisory group on complex pricing

The PRMA Consulting team are excited to launch the inaugural meeting of our expert advisory group focused on complex pricing. The group will look at recent and emerging US experience with CAR-Ts and evaluate potential pricing models in the EU. We will also discuss the challenges and opportunities to indication-specific pricing in Europe. We will share highlights from this meeting with clients after the holidays.

Contact us to find out more about our advisory groups.


Dec 2017

CAR-Ts: access challenges and opportunities

Following our successful webinar yesterday on ‘Market access considerations for CAR-Ts: insights from ASH’, please find more information about how we can help you with your access challenges and opportunities for CAR-Ts.


Oct 2017

Our Senior Director, Jan McKendrick, discusses the impact of discrepancies between licensing and country-specific reimbursement decisions on patient access to cancer treatment


Jan 2018

Payer perspectives on cell and gene therapies: opportunities and challenges

This new webinar has true cross-functional value for everyone working in market access in the pharmaceutical industry. From non-expert audiences through to subject-matter experts. Professor Stephen Palmer from the University of York will join us to discuss his recent work on the assessment of regenerative medicines and cell therapy, and the UK and EU payer perspective on the potential value of these therapies.


Nov 2017

Patient-centricity: shaping value generation for HTA and market access

With patient-centricity becoming a new paradigm for the pharmaceutical industry, this webinar will examine the role of patient engagement in HTA and market access processes, and how this enhances value generation for drug approvals. Focusing on Europe, we will analyze the different models and guidelines in place.


"Please let your staff who supported us know how appreciative we are of their efforts. From the advisory boards to the GVD development to the modeling efforts and numerous projects, the support and partnership was great. The accomplishment in the UK with NICE is absolutely exceptional."

Therapeutic Area Head, GHE Oncology Therapeutics, at a top-20 pharmaceutical company
Nov 2017

ISPOR Glasgow is nearly upon us! Join us at booth 404 to discuss your market access challenges


Jun 2017

Market access update key learnings from ASCO and EHA 2017

In this webinar, we discuss the evolution of value frameworks, the OCM, and incorporating the patient perspective. We also consider the implications for payers of new data on CAR-Ts; key points to think about when planning for market access of a combination; and how payers might handle products approved on the basis of basket trials.


"Just wanted to say great job presenting today. The commercial team increasingly want to be involved in these discussions and your discussion points and delivery were great for the access and broader team. Thanks for making the information practical and insightful. I think the overall response from the team was very positive and the content will ultimately be incredibly helpful for our strategy."

Senior Manager, Oncology Global Market Access and Pricing, at a top-20 pharmaceutical company
Mar 2017

Market access for PD-1 inhibitors: where are we now?

With three products targeting the PD-1 pathway now approved, and other launches expected in 2017, this webinar will take stock of payers’ reactions to the products. Focusing on Europe, we will look at the decisions that have been made to date and discuss these further.


info@prmaconsulting.com
UK (HQ) +44 (0)1252 786284
US +1 (415) 655 6798

Company registration number: 05893400

Follow us


Corporate members

Terms and conditions
Privacy statement
Cookie policy